Funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.
Alderley Park, UK – 3rd October 2018. Clin-e-cal, an innovative digital health company, today announced the completion of a new funding round to expand its development of a fundamentally new approach to training and compliance in respiratory medicine. The funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.
Clin-e-cal are developing several mobile applications in partnership with pharmaceutical and medical device companies to improve inhaler technique and medication compliance, both well-recognized needs within the respiratory field. Using its patent-pending Tone Analysis technology, the company’s first product, Rafi-Tone, uses gamification techniques to help young children take their medication more effectively.
Clin-e-cal was founded by clinical academic Tariq Aslam, in response to his own son’s breathing problems and his resistance to using his inhaler. The company is a spin-out from The University of Manchester (through its agent for IP commercialisation UMI3 Ltd) and the Manchester University NHS Foundation Trust and maintains strong links to the clinical and academic communities.
Clin-e-cal CEO, Dr Lizzie Crawford, said “We are delighted to have closed this investment and are excited to be able to expand Clin-e-cal by further investing in our partnerships and R+D to maximise the value of our innovative approach addressing significant problems in the management of respiratory disease.”
Dr Vijay Barathan, Life Science Partner, said “We are looking forward to working with the team to advance their portfolio of innovate digital health respiratory applications. Their first product is a great example of how significant medical issues can be solved through the digitization of healthcare.”
Chris Spencer, Digital Health Venture Partner at Catapult and newly appointed Chairman of Clin-e-cal, said “Respiratory disease causes an immense worldwide health burden. For example, as long ago as 2013, the World Health Organisation estimated that 235m people suffered from asthma. I’m privileged to have been asked to assist Clin-e-cal as it helps others better manage their treatment and conditions.”
-ends-
Contact:
Dr Vijay Barathan, Life Science Partner
E: vijay@catapult-ventures.com
T: 01625 344300 M: 07832 350820
About Clin-E-Cal
Clin-e-cal was spun out from The University of Manchester/ Manchester University Foundation Trust in 2015 to commercialise IP applicable to the field of digital sound analysis. It has built on the initial ideas to create a vision which has the opportunity to address significant issues of inhaler technique and compliance in respiratory medicine in a robust, economically effective and globally applicable way. The company is based in Wilmslow, Cheshire.
contact: info@clin-e-cal.com
About GM&C Life Sciences Fund
Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region.
The Fund is the result of a collaboration between Cheshire and Warrington Local Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships and can be invested in ‘Life Science’ businesses across the following sectors:
• Pharmaceuticals
• Biotechnology
• Diagnostics
• Life Science contract research organisations (CRO)
• Healthcare technologies
• Medical devices
With contributions from both private and public-sector partners, the size of the Fund, at launch, is around £31m. Full details can be found at: www.gmclifesciencesfund.com
About Catapult Ventures
Catapult Ventures is an independent venture capital fund manager that has been investing in UK businesses since 2002. Catapult’s owners have operated discrete funds on behalf of public and private sector investors totaling c. £130m, including the GM&C Life Sciences Fund.
Since 2015 Catapult has recorded 11 profitable exits averaging 3.9x money multiple, including Accutronics (9.1x), Lumora (4.7x), Oxford Cryosystems (5.2x), Systems Integration (4.9x), Monica Healthcare (3.6x), BWB Consulting (3.2x*), Hangar7 (3x), Haemostatix (3x*) and Stagecoach (2x). [* expected]
Catapult Ventures and Catapult Ventures Group are trading names of Catapult Ultimate Holdings Ltd, which is the ultimate holding company of Catapult Venture Managers Ltd, which is authorised and regulated by the Financial Conduct Authority.
About Manchester University NHS Foundation Trust
Manchester University NHS Foundation Trust (MFT) is one of the largest acute Trusts in the UK, employing over 20,000 staff.
We are responsible for running a family of nine hospitals across six separate sites, providing a wide range of services from comprehensive local general hospital care through to highly specialised regional and national services
